Valuation: Veru Inc.

Market Cap 45.01M 38.56M 36.08M 33.03M 61.98M 4.31B 62.8M 426M 166M 2.16B 169M 165M 7.16B P/E 2026 *
-2.6x
P/E 2027 * -2.68x
Enterprise Value 45.01M 38.56M 36.08M 33.03M 61.98M 4.31B 62.8M 426M 166M 2.16B 169M 165M 7.16B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
89.63%
Yield 2026 *
-
Yield 2027 * -
1 day+2.33%
1 week-3.30%
Current month+17.86%
1 month+16.81%
3 months+12.34%
6 months+5.60%
Current year+23.36%
1 week 2.52
Extreme 2.52
2.71
1 month 2.16
Extreme 2.16
2.89
Current year 2.05
Extreme 2.05
7.33
1 year 2.05
Extreme 2.05
7.33
3 years 2.05
Extreme 2.05
19.2
5 years 2.05
Extreme 2.05
245.5
10 years 2.05
Extreme 2.05
245.7
Manager TitleAgeSince
Chief Executive Officer 65 2016-10-30
Director of Finance/CFO 67 2012-12-31
Chief Tech/Sci/R&D Officer 64 2018-03-31
Director TitleAgeSince
Chairman 65 2018-02-28
Director/Board Member 68 2016-09-30
Director/Board Member 68 2018-02-28
Date Insider Type Main position Quantity % Market Cap.
8/13/26 Buy

Chief Technology Officer

1,800 0.0112%
12/5/25 Free

Chief Executive Officer

100,000 0.6227%
12/5/25 Free

Director

4,000 0.0249%
Change 5-day change 1-year change 3-year change Capi.($)
+2.33%-3.30%-26.67%-74.86% 45.01M
-3.00%+2.27%+73.26%+109.90% 72.12B
+1.90%+23.53%+59.48%+94.82% 65.85B
+5.12%+25.22%+5.13%-5.86% 29.28B
+0.55%+1.64%-4.63%+480.92% 27.47B
+2.74%+12.98%+54.92%+25.77% 26.7B
+0.47%+6.12%+37.01%-15.31% 20.06B
+1.82%-6.67%+251.36%+388.91% 18.22B
+0.94%+3.36%+15.30%+548.19% 16.4B
+0.73%+5.54%+39.99%+151.77% 13.4B
Average +1.36%+7.20%+50.51%+170.43% 28.95B
Weighted average by Cap. +0.74%+9.48%+58.01%+157.82%

Financials

2026 *2027 *
Net sales - -
Net income -25.1M -21.5M -20.12M -18.42M -34.56M -2.4B -35.02M -238M -92.69M -1.21B -94.25M -92.2M -3.99B -37.1M -31.78M -29.74M -27.22M -51.08M -3.55B -51.76M -351M -137M -1.78B -139M -136M -5.9B
Net Debt - -
Logo Veru Inc.
Veru Inc. is a late clinical-stage biopharmaceutical company focused on developing medicines for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). Its drug development program includes two late-stage novel small molecules: enobosarm and sabizabulin. Enobosarm, a selective androgen receptor modulator, is being developed for two indications: Phase 2b clinical QUALITY study of enobosarm as a treatment to augment fat loss and to prevent muscle loss in sarcopenic obese or overweight elderly patients receiving a GLP-1 RA who are at-risk for developing muscle atrophy and muscle weakness, and Phase 3 ENABLAR-2 clinical trial of enobosarm and abemaciclib for the treatment of androgen receptor positive, estrogen receptor positive and human epidermal growth factor receptor 2 negative metastatic breast cancer in the 2nd line setting. Sabizabulin, a microtubule disruptor, is being developed for treatment of hospitalized patients with viral-induced ARDS.
Employees
20
Date Price Change Volume
26-08-21 US$2.640 +2.33% 177,473
26-08-20 US$2.580 -2.27% 135,492
26-08-19 US$2.640 +1.93% 138,995
26-08-18 US$2.590 -1.52% 119,137
26-08-17 US$2.630 -3.66% 127,169
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
2.640USD
Average target price
24.50USD
Spread / Average Target
+828.03%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. VERU Stock